Clinical trials: Hematopoietic Stem Cell Mobilization
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Delayed Platelet Engraftment, Hematological Diseases
- Trial name
- NCT02240992
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Adenosine Deaminase Severe Combined Immune Deficiency
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human…
- Trial name
- NCT05432310
- Testing
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy Subjects
Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans.
- Trial name
- NCT01765803
- Testing
- Mellaril
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Bone Marrow / Autologous Transplants
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
- Trial name
- NCT01738373
- Testing
- Plerixafor
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
In recent years PBPC have replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation. One of the cited advantages of this procedure is the avoidance of bone marrow harvest, which frequently…
- Trial name
- NCT00067639
- Testing
- Pegfilgrastim (Neulasta), Apheresis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
The primary objective of this study is to evaluate tumor cell mobilization (TCM) with non-pegylated G-CSF alone compared with non-pegylated G-CSF plus plerixafor in patients with multiple myeloma (MM) who are potentially poor…
- Trial name
- NCT01753453
- Testing
- Plerixafor, Granulocyte-colony stimulating factor (G-CSF)
- Where
- 5 sites in Belgium, Estonia and 2 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Sickle Cell Disease
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation.
- Trial name
- NCT05618301
- Testing
- Motixafortide, Natalizumab, Leukapheresis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Mozobil for Autologous Stem Cell Mobilization
The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Stem Cell Mobilization, Autologous Stem Cell Transplantation
- Trial name
- NCT01164345
- Testing
- Plerixafor
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
Lymphoma, Multiple Myeloma
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.
The purpose of this study is to determine the safety of parathyroid hormone in combination with G-CSF when used as a stem cell mobilization regimen for patients who fail to mobilize sufficient progenitor stem cells after one or…
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia
- Trial name
- NCT00299780
- Testing
- Stem cell mobilization
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Hematologic Malignancies
Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
No prospective randomized trials have evaluated the most efficacious dose of cyclophosphamide to mobilize autologous stem cells.
- Trial name
- NCT02139280
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Myeloma
PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
High-dose chemotherapy with autologous stem cell support is the current standard procedure in the first-line treatment in younger patients with myeloma fit for intensive treatment.
- Trial name
- PAV (NCT01220375)
- Testing
- Vinorelbine, G-CSF, & Plerixafor, Vinorelbine and Plerixafor, G-CSF and Plerixafor
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Artery Disease
Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease
This two-part study will determine whether stem cells (primitive cells produced by the bone marrow that can develop into blood cells or other types of cells) can be pushed out into the bloodstream, relocate in the heart, and grow…
- Trial name
- NCT00043628
- Testing
- Stem Cell Mobilization
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Malignant Lymphoma
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
Clinical Hypothesis: It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side effects.
- Trial name
- SCF980266 (NCT01016795)
- Testing
- r-metHuSCF and Filgrastim, Chemotherapy plus Filgrastim
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 32 people
- Sponsor
- Aalborg University Hospital
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Hematologic Malignancies
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to…
- Trial name
- NCT00689884
- Testing
- Pegfilgrastim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lymphoma, Non-Hodgkin, Multiple Myeloma
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100).
- Trial name
- NCT00322387
- Testing
- G-CSF and plerixafor
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Granulomatous Disease X-linked (X-CGD)
Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
- Trial name
- XCGD-MOBI (NCT03055247)
- Testing
- Ibuprofen, Myelostim, Mozobil
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
Non-Hodgkin Lymphoma
Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma
The purpose of this study is to compare the ability of pegfilgrastim vs. filgrastim to mobilize peripheral blood stem cells in patients with Non Hodgkin-lymphoma in an intraindividual study
- Trial name
- NCT00306111
- Testing
- pegfilgrastim
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Hospital Tuebingen
Sickle Cell Disease
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE
The objective of this study is to demonstrate whether high-dose plerixafor can effectively mobilize hematopoietic stem cells in patients with sickle cell disease.
- Trial name
- MobiSCD (NCT07341022)
- Testing
- Plerixafor Dose Escalation
- Volunteers
- 12 people
- Sponsor
- Hospital Israelita Albert Einstein